Table of Contents: CATIE TreatmentUpdate - 2002


Canadian AIDS Treatment Information Exchange
Edited by: Sean Hosein

Jump to Table of Contents

TreatmentUpdate 132: December - Vol. 14, No. 9

English  Françaises
 INTRODUCTION: What's a conference about ?

 INTRODUCTION: Que se passe-t-il lors d'une conférence?

HoseinSR
The large international AIDS conferences tend to organize presentations into several themes or "tracks...

 SIDE EFFECTS: Who gets treatment and... side effects

 EFFETS SECONDAIRES: Les traitements : une question d'accès...et d'effets secondaires

HoseinSR
For many years, particularly in the 1980s when people first heard about AIDS, it was seen as a gay male disease. As a result, some HIV positive women may not have been aware of their infection until serious symptoms appeared and their disease had progressed. Moreover, this stereotype of who-gets-AIDS may have influenced decision-making by some doctors who treat women, who may have been reluctant to test their female patients for HIV.

 SIDE EFFECTS: Protection from nuke side effects

 EFFETS SECONDAIRES: Prévenir les effets indésirables des analogues nucléosidiques

HoseinSR
Nucleoside analogues (nukes or NRTIs) such as AZT, d4T and ddI may be associated with a number of side effects, including the following...

 SIDE EFFECTS: Breaking free from nukes

 EFFETS SECONDAIRES: Pour en finir avec les analogues nucléosidiques

HoseinSR
The strange changes in body shape with the loss of fat under the skin (subcutaneous fat) and increased fat in the belly and breasts combined with increased risk of cardiovascular disease and diabetes is collectively called the "HIV lipodystrophy syndrome." Exactly why these changes occur is not clear. Some changes in body shape, such as the loss of subcutaneous fat in the face, arms and legs are most obvious. This side effect has been blamed on the use of a class of drugs called nukes (nucleoside analogues).

 ADHERENCE: What helps adherence to therapy?

 OBSERVANCE THÉRAPEUTIQUE: Quels facteurs favorisent l'observance thérapeutique?

HoseinSR
Historically, the ability of people with chronic health conditions to take their medication as prescribed and directed, on time, every day — otherwise known as "adherence" or "compliance" — is not good. Skipping a few pills for a few days in a row may not have serious consequences for some people with mildly elevated blood pressure. However, the stakes are much greater in HIV because of the virus' ability to mutate and escape the effects of anti-HIV medication. This can occur when doses are skipped and drug levels fall below the level that keeps HIV suppressed. It is estimated that adherence rates of about 95% are needed by PHAs who are taking highly active antiretroviral therapy (HAART).

 VACCINES: Rub-on vaccine study planned

 VACCINS: Un vaccin topique sera bientôt à l'étude

HoseinSR
Treatment for HIV/AIDS is readily available for most citizens and legal residents of high-income countries. However, the highest proportion of PHAs live in tropical, low-income countries where people can barely access these life-prolonging medications.

 CANCER: Cancer risk falls in some HAART users

 CANCER: Le risque de cancer diminue chez certains patients sous multithérapie

HoseinSR
In high-income countries, the availability of HAART has led to dramatic decreases in deaths from many AIDS-related complications, particularly infections. However, decreases in the risk for certain cancers, such as those of the lymphatic system — NHL or non-Hodgkin's lymphoma — have not been as dramatic in the first few years after HAART was released.

 INFECTIONS: Syphilis - the great masquerader

 INFECTIONS: La syphilis — l'ennemi masqué

HoseinSR
According to doctors in Glasgow, Scotland, syphilis may be more aggressive in HIV positive than HIV negative people. The difficulty in diagnosing syphilis is that it can mimic symptoms of many other diseases.

 INFECTIONS: Is hepatitis C virus going to become a major STD?

 INFECTIONS: L'hépatite C deviendra-t-elle une MTS redoutable?

HoseinSR
Rates of unsafe sex and, not surprisingly, sexually transmitted diseases (STDs) are increasing in Western Europe and North America. British researchers have done a preliminary study that suggests hepatitis C virus (HCV) infection may be increasingly transmitted sexually in HIV positive people.

Table Of Contents

TreatmentUpdate 132: December - Vol. 14, No. 9
INTRODUCTION: What's a conference about ?; SIDE EFFECTS: Who gets treatment and... side effects; SIDE EFFECTS: Protection from nuke side effects; SIDE EFFECTS: Breaking free from nukes; ADHERENCE: What helps adherence to therapy?; VACCINES: Rub-on vaccine study planned; CANCER: Cancer risk falls in some HAART users; INFECTIONS: Syphilis - the great masquerader; INFECTIONS: Is hepatitis C virus going to become a major STD

TreatmentUpdate 131: November - Vol. 14, No. 8
SIDE EFFECTS: The usual suspects; SIDE EFFECTS: A brief history of HIV drug therapy; SIDE EFFECTS: Strange side effects; SIDE EFFECTS: Focus on fat; SIDE EFFECTS: Lots of volunteers needed; SIDE EFFECTS: Lactic acid and nuke damage; SIDE EFFECTS: No nukes please; SIDE EFFECTS: Fat wasting - AZT vs. d4T; SIDE EFFECTS: Sugar blues; SIDE EFFECTS: Predicting body shape changes; SIDE EFFECTS: Niacin for high triglycerides; SIDE EFFECTS: Supplement fix for nelfinavir-related diarrhea

TreatmentUpdate 130: September/October - Vol. 14, No. 7
ANTI-HIV AGENTS - Drug holidays - an overview ; ANTI-HIV AGENTS - Here's a story about a drug holiday ; TOXICITY - Milk thistle and indinavir ; TESTING - Some factors affecting survival in HIV positive women ; ANTI-CANCER AGENTS - A new treatment for Kaposi's sarcoma

TreatmentUpdate 129: August - Vol. 14, No. 6
THE XIV INTERNATIONAL AIDS CONFERENCE - Overview of conferencel; ANTI-HIV AGENTS : American-Italian study produces unexpected results; ANTI-HIV AGENTS : Tenofovir looks good in initial therapy; ANTI-HIV AGENTS : Tenofovir and Videx (ddI) EC — some caution required; ANTI-HIV AGENTS : T-20 shows its potency; ANTI-HIV AGENTS : Efavirenz makes its mark in AIDS; TESTING : Study finds fatigue linked to quality of sleep; TESTING : High liver enzyme levels — a warning about survival?; NUTRITION : Nutrient deficits found in some HIV positive people; NUTRITION : Low zinc intake linked to reduced survival

TreatmentUpdate 128: July - Vol. 14, No. 5
SIDE EFFECTS: Sexual dysfunction in men: A report from France; SIDE EFFECTS: Sexual dysfunction in men: A report from Boston; SIDE EFFECTS: Male sexual dysfunction and HAART — the confusion continues; SIDE EFFECTS: Study finds problems with reporting side effects; ANTI-CANCER AGENTS: Recurring cervical growths; ANTI-HIV AGENTS: Starting therapy: study finds guidelines linked to level of immunity

TreatmentUpdate 127: May/June - Vol. 14, No. 4
ANTI-HIV AGENTS: Delavirdine in rescue regimens; ANTI-HIV AGENTS: Could cimetidine be used as a booster?; ANTI-HIV AGENTS: Teaching adherence to substance users; Fine-tuning saquinavir; ANTI-HIV AGENTS: Invirase vs. Fortovase: unexpected results?; ANTI-HIV AGENTS: Saquinavir once daily; ANTI-HIV AGENTS: Saquinavir with low-dose ritonavir twice daily; ANTI-HIV AGENTS: Highlights from the 3rd International Workshop on Clinical Pharmacology of HIV Therapy

TreatmentUpdate 126: March - Vol. 14, No. 3
SIDE EFFECTS : Protease inhibitors and lipid-lowering drugs -- interactions; Cause of serious illness among HAART-users not clear; Using abacavir to avoid lipid problems; Switching to abacavir to reduce fat wasting; 9th Retrovirus Overview; SIDE EFFECTS : Assessing nuke toxicity; SIDE EFFECTS : Check-ups for the power plant?; SIDE EFFECTS : Damage to the power plant

TreatmentUpdate 125: February - Vol. 14, No. 2
SIDE EFFECTS: Comparing liver toxicity between efavirenz and nevirapine; SIDE EFFECTS: Nevirapine levels may predict toxicity; SIDE EFFECTS: Health Canada advises against kava; SIDE EFFECTS: Birth defect in baby born to efavirenz-user; SIDE EFFECTS: Viagra and grapefruit juice - not a good mix; INFECTION FIGHTERS: Cidofovir and surgery for genital warts; ANTI-HIV AGENTS: Swiss study switching to efavirenz

TreatmentUpdate 124: January - Vol. 14, No. 1
SIDE EFFECTS: Testosterone troubles; SIDE EFFECTS: Growth hormone: Does less equal more?; SIDE EFFECTS: Thyroid troubles in Montreal; SIDE EFFECTS: Thyroid troubles in France; HIGHLIGHTS FROM ICAAC: Directly observed therapy (DOT); HIGHLIGHTS FROM ICAAC: Amprenavir and low-dose ritonavir; HIGHLIGHTS FROM ICAAC: Saquinavir vs. Sustiva once daily; HIGHLIGHTS FROM ICAAC: Tenofovir; HIGHLIGHTS FROM ICAAC: Atazanavir boosts saquinavir; HIGHLIGHTS FROM ICAAC: Atazanavir vs. nelfinavir; HIGHLIGHTS FROM ICAAC: Atazanavir overview; ANTI-HIV AGENTS: Starting HAART and its effect on survival; ANTI-HIV AGENTS: Response to HAART depends on T-cell count; ANTI-HIV AGENTS: Delaying therapy - the pendulum swings back

Copyright / Staff / How to Contact
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2002. ÆGiS . All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS , or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.